AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02772068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istaroxime
Description: Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
Study NCT02772068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Study NCT02772068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT05115994 — intervention group
Intervention type: DEVICE
Intervention: Continous positive airway pressure
Study NCT03353428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LC-CTLs
Description: 2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg via IV, chest or tumor injection each time
Study NCT03920397 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of adipose tissue-derived stem/stromal cells and oral Cholecalciferol supplementation
Description: The investigators will acess area under the curve of C-peptide after a liquid mixed meal (Glucerna®), considering the time 0 (basal), 30, 60, 90 and 120 minutes in each follow-up outpatient visit (3 \[T3\], 6 \[T6\], 12 \[T12\], 18 \[T18\], and 24 \[T24\] months after the adipose tissue-derived stem/stromal cells infusion). Other Clinical and Pancreatic Function Evaluation that wil be assess are: Weight, height, body mass index (BMI), blood pressure, heart frequency, frequency of hypoglycemia and insulin dose/kg of body weight, blood count, lipids, renal and hepatic function, thyroid stimulating hormone, free tyroxine, antithyroglobulin antibody, calcium, phosphorus and 25-Hydroxy Vitamin D.
Study NCT02443298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo for risankizumab
Study NCT02443298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Monoclonal IgG antibody
Study NCT03850886 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacinamide Oral Tablet
Description: Nature's Life Niacinamide 1000 mg
Study NCT03850886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidiabetic
Description: Metformin or Sulphonylurea
Study NCT03850886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidiabetic
Description: Metformin or Sulphonylurea
Study NCT03608800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent fasting
Description: The intervention of two nonconsecutive days of 75% energy restriction per week for 8 weeks
Study NCT03905057 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dornier Aries 2 (with active applicator)
Description: Active ESWT: 5000 shockwaves per session. 2 ESWT sessions per week, 12 sessions in total.
Study NCT03905057 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dornier Aries 2 (with sham applicator)
Description: Sham ESWT - No shockwave administered
Study NCT02139163 — intervention group
Intervention type: OTHER
Intervention: Cohort Study
Study NCT01132144 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial injury
Description: Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.~Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.~Endometrial injury:~* Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.~* Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.~* Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping.
Study NCT01132144 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
Study NCT01686087 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Booster Sessions of EX/RP
Description: 45 minute EXRP booster sessions each month
Study NCT01686087 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Monthly Booster Sessions of EX/RP
Description: 45 minute EXRP booster sessions each month
Study NCT01686087 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Visits with MD and independent evaluators
Description: All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
Study NCT01686087 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Visits with MD and independent evaluators
Description: All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
Study NCT01369290 — intervention group
Intervention type: DRUG
Intervention: Venlafaxine
Description: 75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Study NCT01369290 — intervention group
Intervention type: DRUG
Intervention: bupropion
Description: 150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Study NCT01369290 — intervention group
Intervention type: DRUG
Intervention: escitalopram
Description: 10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Study NCT01369290 — intervention group
Intervention type: OTHER
Intervention: Psychotherapy
Description: Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
Study NCT01369290 — intervention group
Intervention type: DRUG
Intervention: Duloxetine
Description: 30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
Study NCT02030691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal continuous airway positive pressure (nCPAP)
Study NCT02030691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal high frequency percussive ventilation (nHFPV)
Study NCT04487977 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Answering a survey on airway management in COVID-19 patients
Study NCT03952533 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dav
Description: Daily oral administration of a food supplement constituted by α-lipoic acid, magnesium, vitamin B6 and vitamin D in tablets of 1,2 g (Dav®, Lo.Li. Pharma, Rome, Italy)
Study NCT02381535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT02381535 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT02381535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02381535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onalespib
Description: Given IV
Study NCT02381535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02709265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amikacin/fosfomycin
Description: single aerosolized dose
Study NCT02097420 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve
Description: Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
Study NCT04156256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD123-CD33 cCAR T cells
Description: CD123-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CD123 and CD33 CARs.
Study NCT04004923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar hysteroscopy
Description: Unipolar resectoscopes are used in this group and the distention fluid is mannitol
Study NCT04004923 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar hysteroscopy
Description: Bipolar resectoscopes are used in this group and the distention fluid is serum physiologic
Study NCT03918980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.
Study NCT03918980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules will be administered in parts 1,2, 4 and 6.
Study NCT03759223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Problem-Solving Training (E-PST)
Description: E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Randomized participants were assigned 1:1 to E-PST or HLM.
Study NCT03759223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Messages (HLM)
Description: Healthy Living Messages are primary care-congruent messages that consist of simple advice regarding general health behaviors and preventive care. Randomized participants were assigned 1:1 to E-PST or HLM.
Study NCT03759223 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Enhanced Problem-Solving Training (E-PST) (non-randomized)
Description: E-PST is a combined treatment that is comprised of brief problem-solving training and compensatory cognitive skills training. Non-randomized participants were assigned to E-PST only.
Study NCT01470352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doluxetine
Description: 30 mg/d
Study NCT01470352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doluxetine
Description: 30 mg/d
Study NCT01470352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: suger pill 30mg/d
Study NCT01470352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: suger pill 30mg/d
Study NCT00364416 — intervention group
Intervention type: OTHER
Intervention: Any treatment used to treat CHF
Description: Clinical Outcomes of Chronic Decompensated Heart Failure patients
Study NCT02866409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: scalp block
Description: In this group following nerves were blocked-~1. Supra-orbital nerve~2. Supra-trochlear nerve~3. Zygomatico-temporal nerve~4. Auriculo-temporal nerve~5. Posterior auricular branches of the greater auricular Nerve~6. The greater, lesser, and third occipital nerves
Study NCT02866409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infiltration
Description: The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
Study NCT02866409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
Study NCT02866409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
Study NCT02866409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
Study NCT02866409 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
Study NCT00863239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight > 85 kg: 1200 mg/day.
Study NCT00863239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight \< 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight > 85 kg: 1200 mg/day.
Study NCT00863239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locteron™ (controlled-release interferon alpha 2b)
Description: investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
Study NCT00863239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Intron™
Description: commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
Study NCT01501071 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal calibration tube
Description: An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
Study NCT01785472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 200 mg tablet
Study NCT01785472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: Olmesartan 20 mg capsule
Study NCT01785472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of LCZ696
Description: Placebo tablet of LCZ696 200 mg once daily
Study NCT01785472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696
Description: Placebo tablet of LCZ696 200 mg once daily
Study NCT01785472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Olmesartan
Description: Placebo capsule of olmesartan 20 mg once daily
Study NCT01898624 — intervention group
Intervention type: DRUG
Intervention: mirabegron
Description: oral
Study NCT03348319 — intervention group
Intervention type: OTHER
Intervention: radiation
Description: Scanning cadaver organs
Study NCT00417560 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated influenza A/H5N1 vaccine
Study NCT03806452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide
Description: Hydroxycarbamide tablets of 100 and 1000 mg
Study NCT03806452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets of 100 and 1000 mg to mimic hydroxycarbamide tablets
Study NCT02176733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT04151810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP1
Description: Single dose part:~Cohort 1:400 mg/m2; Cohort 2: 500 mg/m2; Cohort 3: 750 mg/m2;~Multi-dose Part:~Starting dose: Cohort 1:400 mg/m2; Cohort 2/3: 500 mg/m2; Maintenance dose: Cohort 1:250 mg/m2, QW; Cohort 2/3: 500 mg/m2, Q2W;
Study NCT04151810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDP1
Description: Starting dose: 400 mg/m2; Maintenance dose: 250 mg/m2,QW;
Study NCT04151810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIP chemotherapy
Description: Paclitaxel: 175 mg/m2 in day 1, Q3W; Ifosfamide: 1200 mg/m2 in day 1, day 2 and day 3, Q3W; Cisplatin: 25 mg/m2 in day 1, day 2 and day 3, Q3W; Participants received TIP chemotherapy up to 6 cycles (21 days per cycle).
Study NCT03858075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-782
Description: oral capsules
Study NCT03858075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study NCT03858075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLU-782 taken with food
Description: oral capsules
Study NCT00618215 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer group educational implementation strategy
Description: Delivery CPG~Education session IQual group~Online training website (individual feed back)~Reminder (flow chart), individual feed back record form~Feed back by email~Registration in practice
Study NCT00375193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amrubicin
Description: Amrubicin 40mg/m\<2> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
Study NCT02618993 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Realization of the V3 block in maxillofacial surgeries
Description: bilateral mandibular block in maxillofacial surgeries
Study NCT02618993 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Realization of the V3 block in maxillofacial surgeries
Description: bilateral mandibular block in maxillofacial surgeries
Study NCT01006811 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided.
Study NCT01006811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified Atkins diet
Description: Modified Atkins Diet administration~1. Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)~2. Fats (e.g. cream, butter, oils, ghee) encouraged.~3. Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.~4. Clear carbohydrate-fluids not restricted.~5. Calcium and multivitamin supplementation will be provided.
Study NCT01260987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional photodynamic therapy
Description: Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
Study NCT01260987 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser assisted PDT
Description: Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
Study NCT03501797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Singing-based rehabilitation
Description: The singing-based rehabilitation is a combination of group-training (16 weeks, 1 x week, 90 min), which utilizes a novel combination of traditional senior choir singing and singing-based speech training protocols, and home training (16 weeks, ≥ 3 x week, ≥ 30 min) in which the choir material is trained with a tablet computer.
Study NCT03501797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care comprises all rehabilitation and care services (e.g. speech therapy, physical and occupational therapy, neuropsychological rehabilitation) received by the patients in the Finnish health care system
Study NCT00726115 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAM-531
Study NCT00726115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT02137200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate pushing
Description: Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
Study NCT02178878 — intervention group
Intervention type: GENETIC
Intervention: Progress, Pain
Description: Progress, Pain
Study NCT02137200 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Delayed pushing
Description: Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
Study NCT02220010 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pancreatic stent
Description: The plastic stent is introduced in the pancreatic duct by a duodenoscope
Study NCT01141296 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: fenofibrate 200 mg PO daily for 1 year
Study NCT01141296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo pill identical to active drug will be given PO once a day for 1 year
Study NCT01623440 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Placebo and fMRI
Description: Pill form, participant dosed one time an hour before fMRI.
Study NCT01623440 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Naltrexone and fMRI
Description: 50 mg pill given one time, one hour before fMRI
Study NCT00058331 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epoetin alfa
Study NCT00096941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab was supplied as a single-use liquid formulation.
Study NCT02070159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 600 mg
Description: Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
Study NCT02070159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel 30 mg
Description: Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.